KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBITDA (2016 - 2025)

Historic EBITDA for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$90.5 million.

  • Xenon Pharmaceuticals' EBITDA fell 5281.73% to -$90.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$316.0 million, marking a year-over-year decrease of 4305.04%. This contributed to the annual value of -$279.3 million for FY2024, which is 3048.02% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' EBITDA is -$90.5 million, which was down 5281.73% from -$83.8 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' EBITDA's 5-year high stood at -$15.6 million during Q3 2021, with a 5-year trough of -$90.5 million in Q3 2025.
  • For the 5-year period, Xenon Pharmaceuticals' EBITDA averaged around -$46.6 million, with its median value being -$48.1 million (2023).
  • In the last 5 years, Xenon Pharmaceuticals' EBITDA crashed by 338266.25% in 2021 and then crashed by 815.74% in 2022.
  • Over the past 5 years, Xenon Pharmaceuticals' EBITDA (Quarter) stood at -$24.8 million in 2021, then tumbled by 74.45% to -$43.3 million in 2022, then fell by 23.92% to -$53.7 million in 2023, then crashed by 44.29% to -$77.5 million in 2024, then fell by 16.85% to -$90.5 million in 2025.
  • Its EBITDA stands at -$90.5 million for Q3 2025, versus -$83.8 million for Q2 2025 and -$64.3 million for Q1 2025.